Untitled

Jerjes‐Sánchez, Carlos; Ramírez-Rivera, Alicia; Arriaga-Nava, Roberto; Iglesias-González, Sigfrido; Gutiérrez, Pedro Zarco; Ibarra-Pérez, Carlos; Martinez, Agustin; Valencia, Salvador; Rosado-Buzzo, A.; Pierzo, Juan A.; Rosas, Emma

doi:10.1023/a:1015227125177

Cited by 26 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Approximately 400,000-500,000 patients receive thrombolytic therapy per year worldwide. Many investigators (10)(11)(12)(13)(14)(15), based on several randomized multicenter clinical trials, recommend 1,500,000 IU as the appropriate dose for the treatment of an acute myocardial infarction. From a clinical perspective, the possible effect of significant deviations from the recommended dose is unknown.…”

Section: Introductionmentioning

confidence: 99%

Analysis of five streptokinase formulations using the euglobulin lysis test and the plasminogen activation assay

Couto

Donato

Nucci

2004

Braz J Med Biol Res

View full text Add to dashboard Cite

Streptokinase, a 47-kDa protein isolated and secreted by most group A, C and G ß-hemolytic streptococci, interacts with and activates human protein plasminogen to form an active complex capable of converting other plasminogen molecules to plasmin. Our objective was to compare five streptokinase formulations commercially available in Brazil in terms of their activity in the in vitro tests of euglobulin clot formation and of the hydrolysis of the plasmin-specific substrate S-2251™. Euglobulin lysis time was determined using a 96-well microtiter plate. Initially, human thrombin (10 IU/ml) and streptokinase were placed in individual wells, clot formation was initiated by the addition of plasma euglobulin, and turbidity was measured at 340 nm every 30 s. In the second assay, plasminogen activation was measured using the plasmin-specific substrate S-2251™. Streptase™ was used as the reference formulation because it presented the strongest fibrinolytic activity in the euglobulin lysis test. The Unitinase™ and Solustrep™ formulations were the weakest, showing about 50% activity compared to the reference formulation. All streptokinases tested activated plasminogen but significant differences were observed. In terms of total S-2251™ activity per vial, Streptase™ (75.7 ± 5.0 units) and Streptonase™ (94.7 ± 4.6 units) had the highest activity, while Unitinase™ (31.0 ± 2.4 units) and Strek™ (32.9 ± 3.3 units) had the weakest activity. Solustrep™ (53.3 ± 2.7 units) presented intermediate activity. The variations among the different formulations for both euglobulin lysis test and chromogenic substrate hydrolysis correlated with the SDS-PAGE densitometric results for the amount of 47-kDa protein. These data show that the commercially available clinical streptokinase formulations vary significantly in their in vitro activity. Whether these differences have clinical implications needs to be investigated.

show abstract